Modelling and expression studies of two novel mutations causing factor V deficiency

Journal:Thrombosis and Haemostasis
ISSN:0340-6245
DOI:http://dx.doi.org/10.1160/TH08-02-0106
Issue:2008: 100/5 (Nov) pp. 727-954
Pages:766-772

Modelling and expression studies of two novel mutations causing factor V deficiency

Daniel Delev1, Anna Pavlova1, Stefan Heinz2, Mathias Costa Blaise3, Tamir Chandra4, Bernd Poetsch1, Erhard Seifried2, Johannes Oldenburg1
1Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany; 2Institute for Transfusion Medicine and Immunohaematology, Red Cross Blood Donor Service, Baden-Wuerttemberg-Hessen, University Clinic Frankfurt, Germany; 3Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska, USA; 4Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Cambridge, UK

Summary

Human coagulation factor V (FV), a non-enzymatic cofactor of the prothrombinase complex, is required for the rapid generation of thrombin. FV deficiency is a rare autosomal recessive bleeding disorder.We describe two novel mutations,Tyr91Asn and Asp2098Tyr, found in two probands with a residual FV activity of 51% and 4%, respectively. Modelling and structural analysis of these mutations were performed following short-duration molecular dynamics (MD) simulation.Asp2098Tyr lead to abolishment of the highly conserved salt bridge Asp2098-Arg2171 presumably required for structural integrity of the C2 domain. MD studies suggest that additional conformational changes resulting from this mutation involve local rearrangements at Tyr2063 and Tyr2064 and so affect the phospholipid-membrane binding. MD modelling of the Try91Asn mutant revealed a conformational change nearby the Cu2+ binding site that could affect overall stabilization of the heavy and light chains.These findings suggest that both mutations influence the structural integrity of FV protein. Transient expression data of wild-type and mutant FV variants in 293T human embryonic kidney cells showed FVspecific activity reduced to 26% for Asp2098Tyr and 56% for Tyr91Asn compared to that of wild-type. Thus, both the data from the short duration molecular dynamic simulation and from expression analysis indicate alterations of the FV protein variants that explain the clinical phenotype.

Keywords

Factor V deficiency, novel mutations, MD simulation, transient expression studies

DOI

http://dx.doi.org/10.1160/TH08-02-0106

You may also be interested in...

1.

I. Guella (1), E. M. Paraboschi (1), W. A. van Schalkwyk (2), R. Asselta (1), S. Duga (1)

Thrombosis and Haemostasis 2011 106 2: 296-303

http://dx.doi.org/10.1160/TH11-03-0149

2.

W. Zheng (1, 2), Y. Liu (2), Y. Luo (2), Z. Chen (2), Y. Wang (2), L. Zhang (2), G. Gao (3), Z. Yao (1)

Thrombosis and Haemostasis 2010 104 3: 536-543

http://dx.doi.org/10.1160/TH09-10-0735



Articles

You've 526 Article(s) in your Basket.

TH 107.5

Clinical Focus on GPIIb/IIIa inhibitors: In the May issue of Thrombosis and Haemostasis Armstrong...

TH 107.4

The April 2012 issue of Thrombosis and Haemostasis TH 107.4 is a Theme Issue by A. Schober, T....

Thrombosis and Haemostasis official organ of Spanish Society for Thrombosis and Haemostasis

Thrombosis and Haemostasis, founded in 1957, has become the official organ of the Spanish Society...